Attenuation imaging for hepatic steatosis in chronic hepatitis B vs metabolic dysfunction-associated steatotic liver disease

Figure 1 Flowchart illustrating patient selection. ATI: Attenuation imaging; CHB: Chronic hepatitis B; MASLD: Metabolic dysfunction–associated steatotic liver disease.

Figure 2 Ultrasound attenuation imaging. In this case, the attenuation coefficient is 0.81 dB × cm^-1 × MHz^-1, with R² of 0.97 as an effective value.

Figure 3 Receiver operating characteristic curves of the attenuation coefficient for detecting different grades of liver steatosis. A: Liver steatosis grade S1 or higher; B: Liver steatosis grade S2 or higher. CHB: Chronic hepatitis B; MASLD: Metabolic dysfunction–associated steatotic liver disease.

Figure 4 Box plot graphs illustrating the distribution of attenuation coefficient with different fibrosis stages within each steatosis grade. A: Liver steatosis grade S0; B: Liver steatosis grade S1; C: Liver steatosis grade S2; D: Liver steatosis grade S3. Boxes represent the 25^th and 75^th percentiles and outlier dots.

Figure 5 Box plot graphs illustrating the distribution of attenuation coefficient with different steatosis grades within each fibrosis stage. A: Fibrosis stage F0 and F1; B: Fibrosis stage F2; C: Fibrosis stage F3 and F4. Boxes represent the 25^th and 75^th percentiles and outlier dots.

Figure 6 Receiver operating characteristic curves of the attenuation coefficient of clinical model predicted steatosis ≥ S2 in the metabolic dysfunction-associated steatotic liver disease group. AUC: Area under the curve.